Severe myelosuppression following alopecia shortly after the initiation of 6-mercaptopurine in a patient with Crohn's disease.

A 15-year-old, woman, Crohn's disease patient, who carried the TPMT *3C heterozygous mutant, complained of alopecia 3 days after starting 6-mercaptopurine (6-MP) and then developed severe myelosuppression 6 weeks after starting 6-MP. The alopecia involved scalp hair only (body hair preserved) and was dominant in the temporal region. Following these side effects, transient remission of Crohn's disease occurred. Myelosuppression due to 6-MP is a rare but life-threatening side effect that is difficult to predict despite continuous monitoring of complete blood cell counts. In the present case, 6-MP-induced alopecia preceded myelosuppression and progressed rapidly as the myelosuppression worsened.

[1]  S. Yun,et al.  Hair Loss Pattern due to Chemotherapy-Induced Anagen Effluvium: A Cross-Sectional Observation , 2007, Dermatology.

[2]  L. Hogarth,et al.  The thiopurines: An update , 2005, Investigational New Drugs.

[3]  T. Iga,et al.  Frequency Distribution of Thiopurine S-Methyltransferase Activity in Red Blood Cells of a Healthy Japanese Population , 2004, Therapeutic drug monitoring.

[4]  L. Lennard,et al.  TPMT in the treatment of Crohn's disease with azathioprine , 2002, Gut.

[5]  H. McLeod,et al.  Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. , 2001, Pharmacogenetics.

[6]  M. Hiratsuka,et al.  Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. , 2000, Mutation research.

[7]  R. Modigliani,et al.  Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. , 2000, The Cochrane database of systematic reviews.

[8]  Dorr Vj.  A practitioner's guide to cancer-related alopecia , 1998 .

[9]  V. Dorr.  A practitioner's guide to cancer-related alopecia. , 1998, Seminars in oncology.

[10]  F. Seibold,et al.  Polymyositis, alopecia universalis, and primary sclerosing cholangitis in a patient with Crohn's disease. , 1996, Journal of clinical gastroenterology.

[11]  G. Fick,et al.  Azathioprine and 6-Mercaptopurine in Crohn Disease , 1995, Annals of Internal Medicine.

[12]  G. Fick,et al.  Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. , 1995, Annals of internal medicine.

[13]  B. Korelitz,et al.  The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. , 1994, The American journal of gastroenterology.

[14]  S. Meltzer,et al.  6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. , 1989, Annals of internal medicine.

[15]  P. Whorwell,et al.  Alopecia totalis in a patient with Crohn's disease and its treatment with azathioprine. , 1989, Postgraduate medical journal.